Abstract
Kynurenic acid (KYNA) is found in large amounts after tryptophan load, because tryptophan-2, 3-dioxygenase (EC 1.13.11.11), present in the liver, opens its indole ring, while kynurenine transaminase (EC 2.6.1.7) is able to catalyze the transformation of kynurenine to KYNA. In the last few years, it was demonstrated that KYNA is an important endogenous antagonist of excitatory amino acid receptors (Ganong et al., 1983; Stone and Burton, 1988) and that it reduces cerebral ischemic effects when administered at high dosages in vivo (Germano et al., 1987). Unfortunately, tryptophan is not a good precursor of cerebral KYNA, because it simultaneously increases kynurenine and quinolinic acid, two well-known pro-convulsant agents (Lapin, 1983; Foster et al., 1984). On the other hand, indole-3-pyruvic acid (IPA), the keto-analog of tryptophan, increases KYNA content in several rat organs after i.p. injection (Russi et al., 1989). Inside the brain, conversion to KYNA appears more effective for IPA than for tryptophan, suggesting a different metabolic pathway. Experiments were therefore performed in order to find the new pathway leading from IPA to KYNA.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.